Based on the way Wall Street works, I expect MNTA will be driven down a bit more during October into the $13s/share range, then surge at the end of the month when m-enoxaparin sales figures are released. This will soon be followed by one or more analysts saying they have good information that Teva will soon have their version of Lovenox approved, which will drive MNTA price down again. Of course MNTA will keep accumulating cash but the cycle will repeat in the next quarter with difference being that the baseline MNTA price will be higher. Just my two cents.
Market Data 
Markets 
AI
